title: In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
abstract: The activity of telavancin and comparators was assessed against a contemporary (2007 and 2008) global collection of 10,000 isolates of Staphylococcus aureus. Telavancin was very active against methicillin-susceptible and -resistant S. aureus (MSSA and MRSA, respectively; MIC(50/90) for both, 0.12/0.25 microg/ml; 100.0% susceptible). This agent was 2-, 4-, and 8-fold more potent than daptomycin (MIC(90), 0.5 microg/ml), vancomycin or quinupristin-dalfopristin (MIC(90), 1 microg/ml), and linezolid (MIC(90), 2 microg/ml) against MRSA, respectively. These data show a potent activity of telavancin tested against a current global collection of S. aureus.
authors.affiliation: JMI Laboratories, North Liberty, IA 52317, USA. rodrigo-mendes@jmilabs.com
authors.forename: Rodrigo E
authors.initials: RE
authors.lastname: Mendes
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Moet
authors.forename: Mike J
authors.initials: MJ
authors.lastname: Janechek
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D006801:Humans; D066298:In Vitro Techniques; D000069349:Linezolid; D000077427:Lipoglycopeptides; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D014640:Vancomycin / Q000494:pharmacology; D014769:Virginiamycin / Q000494:pharmacology
chemical_list: D000081:Acetamides; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; D023303:Oxazolidinones; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D014640:Vancomycin; D000069349:Linezolid; D017576:Daptomycin; C487637:telavancin
references.citation: J Antimicrob Chemother. 2008 Jul;62(1):116-21
references.pmid: 18424792
references.citation: Clin Microbiol Infect. 2008 Mar;14 Suppl 2:3-9
references.pmid: 18226084
references.citation: J Antimicrob Chemother. 2006 Aug;58(2):338-43
references.pmid: 16787952
references.citation: Antimicrob Agents Chemother. 2008 Jul;52(7):2647-52
references.pmid: 18443122
references.citation: Clin Microbiol Infect. 2009 Mar;15(3):218-23
references.pmid: 19335369
references.citation: J Clin Microbiol. 2005 Oct;43(10):5285-7
references.pmid: 16207998
references.citation: Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S386-93
references.pmid: 18462094
references.citation: Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011
references.pmid: 18947320
references.citation: Ther Clin Risk Manag. 2008 Feb;4(1):235-44
references.pmid: 18728713
references.citation: J Clin Microbiol. 2004 Jun;42(6):2398-402
references.pmid: 15184410
references.citation: Clin Infect Dis. 2008 Jun 1;46(11):1683-93
references.pmid: 18444791
references.citation: Ann Clin Microbiol Antimicrob. 2007 Oct 30;6:13
references.pmid: 17967199
references.citation: Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8
references.pmid: 18443115
references.citation: Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34
references.pmid: 15728913
references.citation: Antimicrob Agents Chemother. 2007 Sep;51(9):3420-4
references.pmid: 17606689
references.citation: Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83
references.pmid: 19470513